Literature DB >> 12082570

CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia.

H Ujike1, M Takaki, K Nakata, Y Tanaka, T Takeda, M Kodama, Y Fujiwara, A Sakai, S Kuroda.   

Abstract

To examine the cannabinoid hypothesis for pathogenesis of schizophrenia, we examined two kinds of polymorphisms of the CNR1 gene, which encodes human CB1 receptor, a subclass of central cannabinoid receptors, in schizophrenics and age-matched controls in the Japanese population. Allelic and genotypic distributions of polymorphism 1359G/A at codon 453 in the coding region and AAT triplet repeats in the 3' flanking region in the Japanese population were quite different from those in Caucasians. Although the polymorphism 1359G/A was not associated with schizophrenia, the triplet repeat polymorphism of the CNR1 gene was significantly associated with schizophrenia, especially the hebephrenic subtype (P = 0.0028). Hebephrenic schizophrenia showed significantly increased rate of the 9 repeat allele (P = 0.032, OR = 2.30, 95% CI (1.91-2.69)), and decreased rate of the 17 repeat allele (P = 0.011, OR = 0.208, 95% CI (0.098-0.439)). The present findings indicated that certain alleles or genotypes of the CNR1 gene may confer a susceptibility of schizophrenia, especially of the hebephrenic type.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12082570     DOI: 10.1038/sj.mp.4001029

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  64 in total

Review 1.  Cannabinoids and Schizophrenia: Risks and Therapeutic Potential.

Authors:  Marc W Manseau; Donald C Goff
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

2.  Cannabinoid receptor 1 gene polymorphisms and marijuana misuse interactions on white matter and cognitive deficits in schizophrenia.

Authors:  Beng-Choon Ho; Thomas H Wassink; Steven Ziebell; Nancy C Andreasen
Journal:  Schizophr Res       Date:  2011-03-21       Impact factor: 4.939

Review 3.  In vivo imaging of the endocannabinoid system: a novel window to a central modulatory mechanism in humans.

Authors:  Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-11       Impact factor: 9.236

4.  Association of the cannabinoid receptor gene (CNR1) with ADHD and post-traumatic stress disorder.

Authors:  Ake T Lu; Matthew N Ogdie; Marjo-Ritta Järvelin; Irma K Moilanen; Sandra K Loo; James T McCracken; James J McGough; May H Yang; Leena Peltonen; Stanley F Nelson; Rita M Cantor; Susan L Smalley
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-12-05       Impact factor: 3.568

5.  Assessment of Biased Agonism among Distinct Synthetic Cannabinoid Receptor Agonist Scaffolds.

Authors:  Elise Wouters; Jolien Walraed; Michael Joseph Robertson; Max Meyrath; Martyna Szpakowska; Andy Chevigné; Georgios Skiniotis; Christophe Stove
Journal:  ACS Pharmacol Transl Sci       Date:  2019-11-04

Review 6.  What is the mechanism whereby cannabis use increases risk of psychosis?

Authors:  Sonija Luzi; Paul D Morrison; John Powell; Marta di Forti; Robin M Murray
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 7.  Endocannabinoid system: potential novel targets for treatment of schizophrenia.

Authors:  Atsushi Saito; Michael D L Ballinger; Mikhail V Pletnikov; Dean F Wong; Atsushi Kamiya
Journal:  Neurobiol Dis       Date:  2012-12-07       Impact factor: 5.996

8.  Association of polymorphisms of the cannabinoid receptor (CNR1) and fatty acid amide hydrolase (FAAH) genes with heroin addiction: impact of long repeats of CNR1.

Authors:  D Proudnikov; T Kroslak; J C Sipe; M Randesi; D Li; S Hamon; A Ho; J Ott; M J Kreek
Journal:  Pharmacogenomics J       Date:  2009-12-15       Impact factor: 3.550

Review 9.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 10.  Role of endocannabinoid system in mental diseases.

Authors:  Jorge Manzanares; Leyre Urigüen; Gabriel Rubio; Tomás Palomo
Journal:  Neurotox Res       Date:  2004       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.